Antiproteinuric Effects of Liraglutide Treatment

Exclusion Criteria

• •1. SBP \> 180 mm Hg at screening
• •2. Type 1 diabetes mellitus
• •3. Chronic pancreatitis / previous acute pancreatitis
• •4. Known or suspected hypersensitivity to trial product(s) or related products.
• •5. Treatment with oral glucocorticoids, calcineurin inhibitors, dipeptidyl peptidase 4 (DPP4) inhibitors, glucagon like peptide-1 agonists and sodium-glucose co-transporter 2 (SGLT-2) inhibitors, which in the investigator's opinion could interfere with glucose or lipid metabolism 90 days prior to screening
• •6. Cancer (except basal cell skin cancer or squamous cell skin cancer) or any other clinically significant disorder, except for conditions associated with type 2 diabetes history, which in the investigators opinion could interfere with the results of the trial
• •7. Inflammatory bowel disease
• •8. Cardiac disease defined as: Decompensated heart failure (NYHA class III-IV) and/or diagnosis of unstable angina pectoris and/or myocardial infarction within the last 6 months
• •9. Previous bowel resection
• •10. Body mass index \<18.5 kg/m2
• •11. Females of childbearing potential who are pregnant, breast-feeding, intending to become pregnant or not using adequate contraceptive methods
• •12. Clinical signs of diabetic gastroparesis
• •13. Impaired liver function (transaminases \> two times upper reference levels)
• •14. The receipt of any investigational product 90 days prior to this trial
• •15. Known or suspected abuse of alcohol or narcotics
• •16. Subjects with personal or family history of medullary thyroid carcinoma or a personal history of multiple endocrine neoplasia type 2